Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Consolidation in Outsourced Pharmaceutical Services

Skip to the end of the Expertise Menu

Consolidation in Outsourced Pharmaceutical Services

The outsourced pharmaceutical services industry has benefited from recent trends in the pharmaceutical landscape, as traditional drug manufacturers have divested their clinical research, development, and manufacturing assets to focus on core competencies and brand equity. Pharmaceutical companies are increasingly utilizing contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) to manage their drug development processes, from early-stage pre-clinical research and discovery, through large-scale commercialization. In order to obtain and service these highly lucrative sponsorships, middle-market, closely held CROs and CDMOs are turning to both the capital and M&A markets to drive scale and integration within their areas of expertise.

Report Summary
• Introduction
• Trends in Outsourced Pharmaceutical Services
• CDMO Consolidation Trends
• CRO Consolidation Trends
• Concluding Thoughts

Please click below for the Full Report…
[holo_button icon=”” link=”https://www.providenthp.com/wp-content/uploads/2020/03/Consolidation-in-Outsourced-Pharmaceutical-Services.pdf” color=”#003561″ target=”blank”]FULL REPORT[/holo_button]